Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 70.76% from the company’s previous close.

ATXS has been the subject of several other reports. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Down 7.1 %

Shares of NASDAQ ATXS opened at $9.37 on Thursday. The firm’s 50-day simple moving average is $11.40 and its 200 day simple moving average is $10.61. The company has a market cap of $528.66 million, a price-to-earnings ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90.

Institutional Trading of Astria Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ATXS. Vanguard Group Inc. increased its stake in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after acquiring an additional 480,184 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares during the last quarter. American International Group Inc. increased its stake in shares of Astria Therapeutics by 49.4% in the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 8,122 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Astria Therapeutics in the 1st quarter valued at about $200,000. Finally, Tidal Investments LLC acquired a new position in shares of Astria Therapeutics in the 1st quarter valued at approximately $1,664,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.